SG11201909708VA - Methods and antibodies for diabetes-related applications - Google Patents

Methods and antibodies for diabetes-related applications

Info

Publication number
SG11201909708VA
SG11201909708VA SG11201909708VA SG11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
antibodies
methods
street
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Chorev
Jose A Halperin
Original Assignee
Mellitus Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mellitus Llc filed Critical Mellitus Llc
Publication of SG11201909708VA publication Critical patent/SG11201909708VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201909708V 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications SG11201909708VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762488346P 2017-04-21 2017-04-21
PCT/US2018/027856 WO2018195008A1 (en) 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications

Publications (1)

Publication Number Publication Date
SG11201909708VA true SG11201909708VA (en) 2019-11-28

Family

ID=63856388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909708V SG11201909708VA (en) 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications

Country Status (7)

Country Link
US (1) US11866506B2 (https=)
EP (1) EP3612625A4 (https=)
JP (2) JP7303182B2 (https=)
AU (1) AU2018255244A1 (https=)
SG (1) SG11201909708VA (https=)
TW (1) TW201902927A (https=)
WO (1) WO2018195008A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
CN112924682B (zh) * 2019-12-05 2023-02-10 张曼 尿液纤维蛋白原α链蛋白及其多肽片段在正常妊娠中的应用
US11303968B1 (en) 2020-10-09 2022-04-12 Hulu, LLC Personalized ranking of entities in an electronic programming guide for live television
CN112904009B (zh) * 2021-02-19 2022-03-18 山东莱博生物科技有限公司 一种检测糖基化cd59的磁性微球检测试剂盒及其应用
WO2022241236A2 (en) * 2021-05-13 2022-11-17 Mellitus, Llc Methods and reagents for protein analysis
CN115290609B (zh) * 2021-12-22 2024-08-09 温州医科大学 快速检测肝素的试剂及检测方法
CN115144348B (zh) * 2022-07-06 2025-02-14 浙江伊利康生物技术有限公司 糖化白蛋白检测试剂盒、制备方法及其应用方法
WO2024166110A1 (en) * 2023-02-12 2024-08-15 Hadasit Medical Research Services And Development Ltd. Targeted reduction of cd59 for use in treating disease
WO2024254501A1 (en) * 2023-06-07 2024-12-12 Dexcom, Inc. Systems and methods for diabetes prediction
JP2025026011A (ja) 2023-08-10 2025-02-21 株式会社ツジデン 光集光補助フィルム、該光集光補助フィルムを搭載するエッジライト型バックライトユニット、及び該エッジライト型バックライトを搭載する液晶表示装置。

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
FR2619568B1 (fr) 1987-08-21 1989-07-07 Centre Nat Rech Scient Polymeres derives du polystyrene, leurs procedes de preparation et leurs applications pour l'analyse et la purification de molecules d'origine biologique
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9110962D0 (en) 1991-05-21 1991-07-10 Ici Plc Process
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU670108B2 (en) 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US5670377A (en) 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
GB2409456B (en) 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
CA2612303C (en) 2004-06-17 2018-03-13 Jose Halperin Anti-glycated cd59 antibodies and uses thereof
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2007123708A2 (en) 2006-03-31 2007-11-01 Epitome Biosystems, Inc. Post translational modification pattern analysis
WO2007133623A2 (en) 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
JPWO2009051220A1 (ja) * 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
US9527924B2 (en) 2010-06-02 2016-12-27 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
WO2012109538A2 (en) 2011-02-10 2012-08-16 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
CN105102480B (zh) * 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
CN109917125A (zh) * 2013-12-03 2019-06-21 哈佛大学董事会 用于评估妊娠糖尿病的方法和试剂
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications

Also Published As

Publication number Publication date
JP2020517306A (ja) 2020-06-18
AU2018255244A1 (en) 2019-10-31
TW201902927A (zh) 2019-01-16
US11866506B2 (en) 2024-01-09
EP3612625A1 (en) 2020-02-26
JP7303182B2 (ja) 2023-07-04
US20210284751A1 (en) 2021-09-16
WO2018195008A1 (en) 2018-10-25
EP3612625A4 (en) 2021-08-18
JP2023078133A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
SG11201909708VA (en) Methods and antibodies for diabetes-related applications
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201906264YA (en) Improved serum albumin binders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201808775PA (en) Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201908784TA (en) Improved antigen binding receptor formats